ORKA Stock Forecast & Price Target

Oruka Therapeutics is favored because ORKA-001 showed 71.4% PASI 100 at Week 28 and 87.3% PASI 90 after two 600 mg doses, with no injection-site reactions and supportive reproducibility in placebo crossovers, suggesting a differentiated profile versus marketed biologics. Its broader appeal is strengthened by the planned Q6M/Q12M maintenance strategy, the ORKA-002 IL-17A/F program, and the newly announced ORKA-004 TL1A asset, which together expand optionality across psoriasis and other inflammatory indications. Financially, the company reported $1.1B in cash, cash equivalents and marketable securities at the midpoint of 2026, giving it runway through the anticipated BLA filing for ORKA-001 and continued development of ORKA-002.

Oruka Therapeutics is a clinical-stage company whose negative outlook is driven by substantial development and execution risk around ORKA-001 and ORKA-002, including the possibility they fail to reach pivotal trials on time, miss efficacy expectations, or face regulatory delays and approvals risk. The commercial case is also uncertain because the model’s $2.8B peak sales estimate for ORKA-001 and $2.5B for ORKA-002 rests on only a 75% and 40% probability of approval, respectively, while broader I&I competition and slower uptake could pressure returns. Financially, the company recorded a 2Q26 net loss of $0.55 per share, with projected losses widening to $2.54 per share in 2026 and $2.82 per share in 2027, and it will likely need capital markets access, creating dilution risk.